BTK inhibitor

DRUG CLASS:

BTK inhibitor

News alerts, weekly reports and conference planners

Related drugs:

No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	pirtobrutinib Sensitive: A1 - Approval FDA - 1 week (New A1) pirtobrutinib Sensitive : A1 FDA - 1wk	pirtobrutinib Sensitive: A1 - Approval FDA - 1 week pirtobrutinib Sensitive : A1 FDA - 1 week - (New A1)
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	acalabrutinib Sensitive: A2 - Guideline NCCN - 1 week (New A2) acalabrutinib Sensitive : A2 NCCN - 1wk	acalabrutinib Sensitive: A2 - Guideline NCCN - 1 week acalabrutinib Sensitive : A2 NCCN - 1 week - (New A2)
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	ibrutinib + rituximab Sensitive: A1 - Approval ibrutinib + rituximab Sensitive : A1	ibrutinib + rituximab Sensitive: A1 - Approval ibrutinib + rituximab Sensitive : A1
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	orelabrutinib Sensitive: A1 - Approval orelabrutinib Sensitive : A1	orelabrutinib Sensitive: A1 - Approval orelabrutinib Sensitive : A1
No biomarker	Small Lymphocytic Lymphoma	No biomarker	Small Lymphocytic Lymphoma	orelabrutinib Sensitive: A1 - Approval orelabrutinib Sensitive : A1	orelabrutinib Sensitive: A1 - Approval orelabrutinib Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	orelabrutinib Sensitive: A1 - Approval orelabrutinib Sensitive : A1	orelabrutinib Sensitive: A1 - Approval orelabrutinib Sensitive : A1
No biomarker	Waldenstrom Macroglobulinemia	No biomarker	Waldenstrom Macroglobulinemia	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1
No biomarker	Small Lymphocytic Lymphoma	No biomarker	Small Lymphocytic Lymphoma	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1
No biomarker	Waldenstrom Macroglobulinemia	No biomarker	Waldenstrom Macroglobulinemia	ibrutinib + rituximab Sensitive: A1 - Approval ibrutinib + rituximab Sensitive : A1	ibrutinib + rituximab Sensitive: A1 - Approval ibrutinib + rituximab Sensitive : A1
No biomarker	Waldenstrom Macroglobulinemia	No biomarker	Waldenstrom Macroglobulinemia	ibrutinib Sensitive: A1 - Approval ibrutinib Sensitive : A1	ibrutinib Sensitive: A1 - Approval ibrutinib Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	ibrutinib Sensitive: A1 - Approval ibrutinib Sensitive : A1	ibrutinib Sensitive: A1 - Approval ibrutinib Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	ibrutinib + obinutuzumab Sensitive: A1 - Approval ibrutinib + obinutuzumab Sensitive : A1	ibrutinib + obinutuzumab Sensitive: A1 - Approval ibrutinib + obinutuzumab Sensitive : A1
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	ibrutinib Sensitive: A1 - Approval ibrutinib Sensitive : A1	ibrutinib Sensitive: A1 - Approval ibrutinib Sensitive : A1
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	ibrutinib Sensitive: A1 - Approval ibrutinib Sensitive : A1	ibrutinib Sensitive: A1 - Approval ibrutinib Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	obinutuzumab + acalabrutinib Sensitive: A1 - Approval obinutuzumab + acalabrutinib Sensitive : A1	obinutuzumab + acalabrutinib Sensitive: A1 - Approval obinutuzumab + acalabrutinib Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	acalabrutinib Sensitive: A1 - Approval acalabrutinib Sensitive : A1	acalabrutinib Sensitive: A1 - Approval acalabrutinib Sensitive : A1
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	acalabrutinib Sensitive: A1 - Approval acalabrutinib Sensitive : A1	acalabrutinib Sensitive: A1 - Approval acalabrutinib Sensitive : A1
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	acalabrutinib Sensitive: A1 - Approval acalabrutinib Sensitive : A1	acalabrutinib Sensitive: A1 - Approval acalabrutinib Sensitive : A1
No biomarker	Small Lymphocytic Lymphoma	No biomarker	Small Lymphocytic Lymphoma	ibrutinib + rituximab Sensitive: A1 - Approval ibrutinib + rituximab Sensitive : A1	ibrutinib + rituximab Sensitive: A1 - Approval ibrutinib + rituximab Sensitive : A1
No biomarker	Small Lymphocytic Lymphoma	No biomarker	Small Lymphocytic Lymphoma	ibrutinib Sensitive: A1 - Approval ibrutinib Sensitive : A1	ibrutinib Sensitive: A1 - Approval ibrutinib Sensitive : A1
No biomarker	Small Lymphocytic Lymphoma	No biomarker	Small Lymphocytic Lymphoma	acalabrutinib Sensitive: A1 - Approval acalabrutinib Sensitive : A1	acalabrutinib Sensitive: A1 - Approval acalabrutinib Sensitive : A1
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	acalabrutinib Sensitive: A1 - Approval acalabrutinib Sensitive : A1	acalabrutinib Sensitive: A1 - Approval acalabrutinib Sensitive : A1
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	ibrutinib Sensitive: A1 - Approval ibrutinib Sensitive : A1	ibrutinib Sensitive: A1 - Approval ibrutinib Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	venetoclax + ibrutinib Sensitive: A1 - Approval venetoclax + ibrutinib Sensitive : A1	venetoclax + ibrutinib Sensitive: A1 - Approval venetoclax + ibrutinib Sensitive : A1
TP53 mutation	Small Lymphocytic Lymphoma	TP53 mutation	Small Lymphocytic Lymphoma	zanubrutinib Sensitive: A2 - Guideline zanubrutinib Sensitive : A2	zanubrutinib Sensitive: A2 - Guideline zanubrutinib Sensitive : A2
Chr del(17p)	Small Lymphocytic Lymphoma	Chr del(17p)	Small Lymphocytic Lymphoma	zanubrutinib Sensitive: A2 - Guideline zanubrutinib Sensitive : A2	zanubrutinib Sensitive: A2 - Guideline zanubrutinib Sensitive : A2
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	zanubrutinib Sensitive: A2 - Guideline zanubrutinib Sensitive : A2	zanubrutinib Sensitive: A2 - Guideline zanubrutinib Sensitive : A2
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	zanubrutinib Sensitive: A2 - Guideline zanubrutinib Sensitive : A2	zanubrutinib Sensitive: A2 - Guideline zanubrutinib Sensitive : A2
Chr del(11q)	Chronic Lymphocytic Leukemia	Chr del(11q)	Chronic Lymphocytic Leukemia	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	venetoclax + ibrutinib Sensitive: A2 - Guideline venetoclax + ibrutinib Sensitive : A2	venetoclax + ibrutinib Sensitive: A2 - Guideline venetoclax + ibrutinib Sensitive : A2
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2

BTK inhibitor

BTK inhibitor

Associations(293)

Associations
(293)